在对标准剂量伊马替尼耐药的急变期慢性髓性白血病患者中，十四酰佛波醇乙酸酯（TPA）与伊马替尼之间的协同相互作用。

Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.

作者信息

Fang Baijun, Song Yongping, Han Zhengtao, Wei Xudong, Lin Quande, Zhu Xiaoxiu, Yang Ruyu, Sun Junzhong, Tian Guofeng, Liu Xinjian, Cao Guoshun, Shi Yin, Nie Neng, Li Dapeng, Zhao Robert Chunhua

机构信息

Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School, Henan University, 127 Dongming Road, Zhengzhou 450008, China.

出版信息

Leuk Res. 2007 Oct;31(10):1441-4. doi: 10.1016/j.leukres.2007.02.004. Epub 2007 Mar 23.

DOI:10.1016/j.leukres.2007.02.004

PMID:17383001

Abstract

We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D(3) (VD(3)) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400mg/day). The results suggested that TPA combined with imatinib (400mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

摘要

我们已经证明，12-0-十四烷酰佛波醇-13-乙酸酯（TPA）联合维生素D3（VD3）和阿糖胞苷（Ara C）对急变期慢性髓性白血病（CML）是有效且可行的。在本研究中，我们对标准剂量伊马替尼（400mg/天）耐药的CML急变期患者，研究了TPA联合伊马替尼（甲磺酸伊马替尼）抑制剂的疗效。结果表明，TPA联合伊马替尼（400mg/天）可能克服对常规剂量治疗反应不佳的情况。因此，这种方法作为新诊断CML的一线治疗值得进一步评估。